New England Journal of Medicine

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

New England Journal of Medicine
May 2, 2025, 17:41 | Science
Wade Swenson: A Must-Read on the Ethical Integration of AI in Medicine
Wade Swenson, Program Manager at ACCC and Founder of Rural Cancer Institute, shared a post…
Apr 10, 2025, 16:44 | Insight
Prostate cancer spit test is better for men with high genetic risk than the standard PSA blood test - ICR
The Institute of Cancer Research (ICR) shared a post on LinkedIn: "Breaking News: Prostate cancer…
Feb 10, 2025, 18:20 | Science
Leela Morená: Xenotransplantation of a porcine kidney for end-stage kidney disease
Leela Morená, Postdoctoral Research Fellow at Harvard Medical School, shared a post on X about…
Feb 9, 2025, 15:33 | Science
Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors
Michael Duruisseaux,  Physician-Scientist in the Onco-Pharmacology team at the Lyon Cancer Research Center, shared an…
Feb 8, 2025, 06:50 | Science
Stephen V Liu: Results from the phase II study of zenocutuzumab in NRG1 fusion+ cancers
Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and…
Jan 11, 2025, 21:11 | Insight
Adding Blinatumomab to Standard Treatment for Pediatric B-cell ALL
Children's Hospital of Philadelphia Research Institute shared a post on LinkedIn: "Following a Phase 3…
Jan 10, 2025, 08:39 | Insight
Manufactured Chemicals and Children’s Health - The Need for New Law
Henry Rowlands, Chief Executive Officer of Soil in Formation, shared a post on LinkedIn about…
Jan 1, 2025, 16:13 | Insight
Vivek Subbiah: The NEJM Group 2024 Notable Articles collection is out
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Dec 25, 2024, 09:10 | Science
Greg J. Fox: Levofloxacin's safety for preventing multidrug-resistant TB
Greg J. Fox, Professor of Respiratory Medicine and Interim Director of Sydney Southeast Asia Centre…
Dec 17, 2024, 21:21 | Blog
Fadila Kouhen: Practice changing insight for local treatment of breast cancer
Fadila Kouhen, Associate Professor at Cheikh Khalifa International University Hospital, posted the following on LinkedIn: “Practice…
Dec 9, 2024, 14:03 | Blog
Abnormal prenatal blood test results could indicate hidden maternal cancers
The National Institutes of Health (NIH) revealed that abnormal prenatal blood test results may point…
Nov 4, 2024, 17:12 | Drugs
Talha Badar: Current FDA label for asciminib
Talha Badar, Hematologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X: ''Deep dive…
Nov 2, 2024, 21:28 | Insight
Yan Leyfman: Inavolisib with palbociclib–fulvestrant for PIK3CA-mutated, HR+, HER2- breast cancer
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about…
Oct 26, 2024, 10:17 | Blog
Revival of Radiation Therapy for Inflammatory Conditions, suggested by Matthew Katz
Matthew Katz, Radiation Oncologist at Tufts Medical Center, shared a post on X: "Interest in…
Oct 19, 2024, 16:52 | Blog
9 out of 10 patients who got the immunotherapy for Hodgkin Lymphoma were in remission after two years - Wilmot Cancer Institute
Wilmot Cancer Institute recently posted on LinkedIn: “Exciting news! A new study just published in…
Oct 11, 2024, 20:50 | Blog
Monica Bertagnolli: Repurposed Cancer Drug Shows Effectiveness in Treating Rare Blood Vessel Disorder
Monica Bertagnolli recently shared a post about repurposed cancer drug effects in treating rare blood vessel…
Oct 7, 2024, 15:53 | Insight
Pembrolizumab vs. Observation in Muscle-Invasive Urothelial Carcinoma
Tres Uramigas shared on X: “Sure! Here’s the post without the usernames: AMBASSADOR: Phase III…
Oct 7, 2024, 11:42 | Blog
Results after Four Years of Screening for Prostate Cancer with PSA and MRI - NEJM
NEJM (New England Journal of Medicine) shared a post on X, about recent papers published…
Oct 6, 2024, 13:39 | Insight
Sabine Brookman-May: SWOGS1011 finally published in NEJM
Sabine Brookman-May shared a post on X by NEJM about a recent paper by Seth…
Sep 23, 2024, 15:50 | Insight
Guru Sonpavde: ESMO24 bladder cancer practice-changing highlight
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 17, 2024, 15:03 | Blog
Vivek Subbiah: Now that we have landed in the moon off to Mars
Vivek Subbiah shared a post on X: ''To the moon! Huge congratulations to Toni Choueiri…
Sep 16, 2024, 14:34 | Insight
New standard of care for Limited-Stage Small-Cell Lung Cancer, summary by Estela Rodriguez 
Estela Rodriguez shared a post on X: "Out today in ADRIATIC New England Journal of Medicine…
Sep 12, 2024, 09:59 | Insight
Doxorubicin–Trabectedin with Trabectedin maintenance in Leiomyosarcoma
Vivek Subbiah shared a post on X about a recent paper by Patricia Pautier et al., commenting: “Doxorubicin–Trabectedin…
Sep 9, 2024, 13:41 | Dialogues
Dr. Vivek Subbiah on Pioneering Precision Oncology and Global Clinical Trials | OncoInfluencers #13
Dr. Vivek Subbiah, Chief of Early Phase Drug Development at Sarah Cannon Research Institute, joins…
Aug 25, 2024, 13:02 | Insight
Toni Choueiri: Results from LITESPARK-005 are out
Toni Choueiri shared a post on X about a recent paper titled "Belzutifan versus Everolimus…
Aug 1, 2024, 15:35 | Insight
Harold Burstein: Thoughtful op-ed on multicancer ctDNA genomic screens by Hilary Robbins
Harold Burstein, Breast cancer specialist and Professor at Dana Farber Cancer Institute, shared a post on…
Jul 15, 2024, 08:52 | Blog
Raffaele Colombo: Tisotumab vedotin as 2nd or 3rd line therapy for recurrent cervical cancer
Raffaele Colombo shared a post on X about recent paper by Ignace Vergote et al.…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 26, 2024, 12:05 | Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 24, 2024, 15:19 | Insight
Vivek Subbiah: Precision therapy with ALK inhibitor in ALCL
Vivek Subbiah shared on X:          .  "Precision therapy with anaplastic lymphoma…
Jun 23, 2024, 14:07 | Blog
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
Mark Roschewski, Senior Clinician in the Lymphoid Malignancies Branch at the National Cancer Institute, shared a…
Jun 20, 2024, 07:48 | Blog
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Vivek Subbiah shared a post on X: "Risk of Second Tumors and T-Cell Lymphoma after CAR…
Jun 8, 2024, 02:16 | Blog
Toni Choueiri: NICHE-2 by Myriam Chalabi published in NEJM
Toni Choueiri shared a post on X:             , "NICHE-2 published…
May 13, 2024, 08:08 | Blog
Monica Bertagnolli: Fascinating research I recently read about CAR-T therapy
Monica Bertagnolli shared a post on LinkedIn: ''Fascinating research I recently read about in the New…
May 1, 2024, 17:02 | Opinion
Uri Ilan: This isn't the first time we've seen AI in the exam room
Uri Ilan, Researcher PhD Student, Coordinator of the International Leukemia/Lymphoma Target Board, shared a post…
May 1, 2024, 10:59 | Blog
Michael Kupferman: Madappa Kundranda sat down with Arizona PBS Horizon to discuss a potential new way to screen for colorectal cancer
Michael Kupferman, Senior Vice President at Banner Health, shared a post on LinkedIn: "Banner MD…
Apr 28, 2024, 14:27 | Blog
Michael D. : Meet the Master-Hands of Medicine
Michael D., Support Analyst at Sarah Cannon Research Institute, shared a post by Vivek Subbiah…
Apr 25, 2024, 20:18 | Positive
Vivek Subbiah: HUGE MILESTONE in all of medicine and a huge win for patients and families with sickle cell disease and β-Thalassemia
Quoting Vivek Subbiah's post on X/Twitter: "Hot off the press! HUGE MILESTONE in all of…
Apr 9, 2024, 09:03 | Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Apr 8, 2024, 14:54 | Insight
Piotr Wysocki: New data solidify the idea of omitting axillary dissection in breast cancer patients with clinically N0 disease and macrometastases in 1-2 sentinel LN
Piotr Wysocki, Head of the Clinical Oncology Department at Jagiellonian University Hospital, shared on LinkedIn:…
Apr 7, 2024, 03:41 | Insight
Sarah Sammons: How do we tailor adjuvant therapy without axillary dissection?
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, recently shared a post by Massimo…
Apr 5, 2024, 18:16 | Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Feb 21, 2024, 18:18 | Insight
Vivek Subbiah: As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products
Vivek Subbiah shared on LinkedIn: "Perspective article on 'Secondary Cancers after Chimeric Antigen Receptor T-Cell…
Feb 5, 2024, 11:19 | Insight
Vivek Subbiah: When the New England Journal of Medicine publishes a Phase 1 study in any field, you know it's a game-changer
Vivek Subbiah shared on LinkedIn: ''When the New England Journal of Medicine publishes a Phase 1…
Jan 5, 2024, 15:00 | Blog
An important step in improving the diagnostic challenges in AVP-D - Histiocytosis Association
Histiocytosis Association recently posted on LinkedIn: "We recently learned of a new article on copeptin-based…
Nov 1, 2023, 18:31 | Drugs
David Sebag-Montefiore: We strongly caution against the use of FOLFOX alone applied to the whole PROSPECT trial population
David Sebag-Montefiore shared on LinkedIn: "Delighted to see our letter published in the New England Journal…
Sep 3, 2023, 17:26 | Opinion
Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.
Paz Polak, VP of Computational Biology, C2i Genomics, recently posted on LinkedIn: "In a correspondence…
All: 47 Posts: 1 - 100
Special Coverage